- Raw materials
- D-chiro-Inositol
Filters
Custom request?
Type
Production region
Qualifications
Country of origin
D-chiro-Inositol API Manufacturers & Suppliers
1 verified results
All D-chiro-Inositol data. Full access. Full negotiation power
Commercial-scale Suppliers
Employees: 50+
All certificates
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
D-chiro-Inositol | CAS No: 643-12-9 | GMP-certified suppliers
A medication that is under investigation for potential benefits in managing polycystic ovary syndrome and related metabolic and endocrine disorders.
Product Snapshot
- D-chiro-Inositol is an oral small molecule formulation
- It is primarily investigated for metabolic and endocrinological applications
- The compound is currently in investigational status without approved regulatory market authorization
Clinical Overview
The clinical indication for D-chiro-Inositol has not been formally established, and its pharmacodynamics and mechanism of action remain to be fully elucidated. It is classified as an investigational substance, and no regulatory approvals have been granted for therapeutic use at this time.
From a pharmacological perspective, inositol stereoisomers like D-chiro-Inositol are implicated in various intracellular signaling pathways, including insulin signal transduction, which may underlie their potential utility in metabolic and endocrine disorders. However, specific mechanisms by which D-chiro-Inositol exerts biological effects are yet to be comprehensively characterized.
Key absorption, distribution, metabolism, and excretion (ADME) parameters for D-chiro-Inositol have not been widely reported, limiting detailed understanding of its pharmacokinetic profile. Likewise, safety and toxicity data remain preliminary, and no definitive safety conclusions can be drawn at this stage. Any use should be confined to well-monitored clinical research settings.
Currently, there are no notable brand names associated with D-chiro-Inositol as a pharmaceutical entity, reflecting its investigational status.
For API procurement, stringent quality control is imperative due to the investigational nature of D-chiro-Inositol. Sourcing should ensure compliance with relevant pharmacopeial standards where applicable, verification of stereoisomeric purity, and adherence to good manufacturing practices (GMP) to support clinical and regulatory requirements.
Identification & chemistry
| Generic name | D-chiro-Inositol |
|---|---|
| Molecule type | Small molecule |
| CAS | 643-12-9 |
| UNII | 6R79WV4R10 |
| DrugBank ID | DB15350 |
Formulation & handling
- D-chiro-Inositol is a small molecule with high water solubility, suitable for oral formulations.
- Its low LogP value indicates low lipophilicity, suggesting limited membrane permeability which may affect bioavailability.
- Stability handling is generally straightforward due to the compound's small molecule nature and investigational status requires close monitoring of formulation performance.
Regulatory status
D-chiro-Inositol API manufacturers & distributors
Compare qualified D-chiro-Inositol API suppliers worldwide. We currently have 1 companies offering D-chiro-Inositol API, with manufacturing taking place in 1 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| Sinoway industrial Co.,Lt... | Distributor | China | China | CoA | 757 products |
When sending a request, specify which D-chiro-Inositol API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality D-chiro-Inositol API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
